Evandro Chagas Institute of Clinical Research Report issue

Academic/Hospital Phase 1 Phase 3

Organization Overview

First Clinical Trial
2013
NCT01863576
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Alejandro Marcel Hasslocher, MD MSc PhD student | Andrea Pereira de Souza, PhD | Andrea Silvestre de Sousa, MD PhD | Beatriz Grinsztejn | Claudia Santos de Aguiar Cardoso, MSc | Patricia Dias de Brito, PhD | Paula Simplicio da Silva, MSc PhD student | Pedro Emmanuel Alvarenga Americano do Brasil, MD PhD | Roberta Olmo Pinheiro, PhD | Sergio Salles Xavier, MD PhD

Active Ingredients

Drugs in Phase 3 Trials (1)

cabotegravir (Vocabria) (1 trial)

Drugs in Phase 1 Trials (1)

icosapent ethyl (vascepa) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cardiomyopathies (Phase 1)

Chagas Cardiomyopathy (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2